Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma.

Journal: Journal of ovarian research
Published Date: May 19, 2025

Abstract

BACKGROUND: Epithelial ovarian cancer (EOC) is a deadly and heterogenous disease comprising five major histotypes: clear cell carcinoma (CCC), endometrioid carcinoma (EC), low- and high-grade serous carcinoma (LGSC, HGSC), and mucinous carcinoma (MC). Despite this heterogeneity, EOC is often treated as a homogenous disease, and reliable screening tests are lacking. Although progress has been made, there is a pressing need for biomarkers to refine patient stratification, guide treatment, and improve outcomes. Here, we elucidated the relationship between DNA methylation and gene expression patterns in EOC to identify histotype-specific biomarkers.

Authors

  • Hugo Swenson
    Department of Oncology, Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden. hugo.swenson@gu.se.
  • Ella Ittner
    Department of Oncology, Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
  • Lucas Werner
    Department of Oncology, Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
  • Elisabeth Werner Rönnerman
    Department of Clinical Pathology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Claudia Mateoiu
    Department of Clinical Pathology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Anikó Kovács
    Department of Clinical Pathology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Pernilla Dahm-Kähler
    Department of Obstetrics and Gynecology, Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
  • Ghassan M Saed
    Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
  • Szilárd Nemes
    AstraZeneca, Gothenburg, Sweden.
  • Per Karlsson
    Department of Oncology, Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
  • Toshima Z Parris
    Department of Oncology, Sahlgrenska Academy, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
  • Khalil Helou
    Department of Nutrition, Faculty of Pharmacy, Medical Sciences Campus, Saint Joseph University of Beirut, Damascus RoadRiad Solh, P.O. Box 115076, Beirut, 1107 2180, Lebanon.

Keywords

External Resources

Popular Topics
Recent Journals